​

Mirum Pharmaceuticals (MIRM) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChartTranscripts

MIRM Stock Forecast


Mirum Pharmaceuticals (MIRM) stock forecast, based on 18 Wall Street analysts, predicts a 12-month average price target of $155.80, with a high of $202.00 and a low of $130.00. This represents a 64.68% increase from the last price of $94.61.

$50 $90 $130 $170 $210 $250 High: $202 Avg: $155.8 Low: $130 Last Closed Price: $94.61

MIRM Stock Rating


Mirum Pharmaceuticals stock's rating consensus is Buy, based on 18 Wall Street analysts. The breakdown includes 1 Strong Buy (5.56%), 17 Buy (94.44%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 18 0 17 1 Strong Sell Sell Hold Buy Strong Buy

MIRM Price Target Upside V Benchmarks


TypeNameUpside
StockMirum Pharmaceuticals64.68%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends


1M3M12M
# Anlaysts61144
Avg Price Target$174.17$164.18$138.39
Last Closing Price$94.61$94.61$94.61
Upside/Downside84.09%73.53%46.27%
Ratings Trends

DateStrong BuyBuyHoldSellStrong SellTotal
Nov, 26410---14
Oct, 26410---14
Sep, 26410---14
Aug, 2649---13
Jul, 26410---14
Analyst Price Target Forecasts

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 04, 2026Swayampakula RamakanthH.C. Wainwright$202.00$87.03132.10%113.51%
Nov 04, 2026Steven SeedhouseRaymond James$189.00$87.03117.17%99.77%
Oct 14, 2026Stifel Nicolaus$156.00$79.9695.10%64.89%
Oct 13, 2026Evercore ISI$146.00$83.5874.68%54.32%
Oct 12, 2026Morgan Stanley$152.00$86.0676.62%60.66%
Oct 12, 2026H.C. Wainwright$200.00$84.59136.43%111.39%
Oct 08, 2026RBC Capital$155.00$79.1995.73%63.83%
Sep 29, 2026Robert W. Baird$130.00$87.9647.79%37.41%
Sep 28, 2026Morgan Stanley$144.00$87.9663.71%52.20%
Sep 28, 2026H.C. Wainwright$195.00$87.00124.14%106.11%
Analyst Rating Forecasts

DateCompanyPrevious RatingNew RatingRating Change
Nov 04, 2026H.C. WainwrightBuyBuyhold
Nov 04, 2026Raymond JamesStrong BuyStrong Buyhold
Oct 13, 2026Evercore ISIOutperformOutperformhold
Oct 12, 2026Morgan StanleyOverweightOverweighthold
Oct 12, 2026Cowen & Co.BuyBuyhold
Oct 08, 2026RBC CapitalOutperformOutperformhold
Sep 29, 2026CitigroupBuyBuyhold
Sep 28, 2026CitigroupMarket OutperformMarket Outperformhold
Sep 28, 2026H.C. WainwrightBuyBuyhold
Aug 27, 2026CitigroupMarket OutperformMarket Outperformhold

Financial Forecast


EPS Forecast

$-10 $-6 $-2 $2 $6 $10 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.77$-4.01$-4.00$-1.85$-0.47---
Avg Forecast$-4.48$-4.03$-3.37$-1.62$-0.62$0.62$2.92$4.97
High Forecast$-4.10$-3.79$-3.07$-0.43$0.83$4.99$6.98$5.97
Low Forecast$-5.21$-4.65$-3.62$-1.98$-1.28$-1.13$0.49$4.54
Surprise %-38.17%-0.50%18.69%14.20%-24.19%---

Revenue Forecast

$0 $300M $600M $900M $1B $2B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$19.14M$77.06M$186.37M$336.89M$521.31M---
Avg Forecast$78.42M$76.00M$184.64M$333.95M$422.98M$521.39M$718.97M$919.96M
High Forecast$88.19M$84.88M$186.67M$336.76M$483.39M$521.39M$830.15M$1.06B
Low Forecast$73.23M$72.47M$179.31M$332.51M$396.78M$521.39M$670.45M$857.89M
Surprise %-75.60%1.40%0.94%0.88%23.25%---

Net Income Forecast

$-250M $-140M $-30M $80M $190M $300M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-83.99M$-135.66M$-163.41M$-87.94M$-23.36M---
Avg Forecast$-183.22M$-164.93M$-136.73M$-49.23M$-36.95M$44.32M$162.92M$203.34M
High Forecast$-167.46M$-154.97M$-125.39M$-17.48M$33.78M$203.99M$285.38M$244.21M
Low Forecast$-212.90M$-189.98M$-148.08M$-80.98M$-52.35M$-46.16M$20.03M$185.50M
Surprise %-54.16%-17.74%19.51%78.64%-36.77%---

MIRM Forecast FAQ


Is Mirum Pharmaceuticals stock a buy?

Mirum Pharmaceuticals stock has a consensus rating of Buy, based on 18 Wall Street analysts. The rating breakdown includes 1 Strong Buy, 17 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Mirum Pharmaceuticals is a favorable investment for most analysts.

What is Mirum Pharmaceuticals's price target?

Mirum Pharmaceuticals's price target, set by 18 Wall Street analysts, averages $155.8 over the next 12 months. The price target range spans from $130 at the low end to $202 at the high end, suggesting a potential 64.68% change from the previous closing price of $94.61.

How does Mirum Pharmaceuticals stock forecast compare to its benchmarks?

Mirum Pharmaceuticals's stock forecast shows a 64.68% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Mirum Pharmaceuticals over the past three months?

  • November 2026: 28.57% Strong Buy, 71.43% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • October 2026: 28.57% Strong Buy, 71.43% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • September 2026: 28.57% Strong Buy, 71.43% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Mirum Pharmaceuticals’s EPS forecast?

Mirum Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2026 is $0.62, marking a -231.91% decrease from the reported $-0.47 in 2025. Estimates for the following years are $2.92 in 2027, and $4.97 in 2028.

What is Mirum Pharmaceuticals’s revenue forecast?

Mirum Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2026 is $521.39M, reflecting a 0.01% increase from the reported $521.31M in 2025. The forecast for 2027 is $718.97M, and $919.96M for 2028.

What is Mirum Pharmaceuticals’s net income forecast?

Mirum Pharmaceuticals's net income forecast for the fiscal year ending in December 2026 stands at $44.32M, representing a -289.68% decrease from the reported $-23.363M in 2025. Projections indicate $162.92M in 2027, and $203.34M in 2028.